Data shared from the Phase III LONESTAR study at the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer reveal that incorporating local consolidative therapy involving surgery or radiation subsequent to dual immunotherapy induction does not enhance overall or progression-free survival for metastatic non-small cell lung cancer.
Challenging the Oligometastatic Paradigm in the LONESTAR Trial
Local consolidative therapy—such as targeted radiation or surgical resection—has traditionally improved outcomes in selected patients with oligometastatic non-small cell lung cancer treated with chemotherapy. However, shifting that clinical paradigm into the era of immune checkpoint inhibitors remained an open scientific question until investigators launched the Phase III LONESTAR trial.
This randomized, open-label, single-center study recruited individuals with metastatic non-small cell lung cancer who had not previously received immunotherapy. Following a 12-week induction phase utilizing nivolumab combined with ipilimumab, participants whose disease had not progressed and who experienced no dose-limiting toxicities were randomized.
The study divided participants into equal groups: 83 individuals were maintained on nivolumab and ipilimumab by themselves, whereas another 83 underwent local consolidative therapy prior to resuming the identical dual immunotherapy protocol.
Mehmet Altan, M.D., of MD Anderson Cancer Center in Houston, Texas, explained the core finding from the study: “In this randomized trial, adding local consolidative therapy after induction dual checkpoint blockade was feasible, but it did not improve overall survival or progression-free survival in the overall population or among patients with oligometastatic disease.”
Of the patients assigned to the local consolidative therapy arm in the trial, 71 received radiation to at least one disease site, and 16 underwent surgery where feasible.
Survival Metrics and Subgroup Outcomes
Data from the June 15, 2026 cutoff point outline clear survival differences that challenge the therapeutic standard. For the entire randomized cohort, median overall survival touched 52.8 months under nivolumab and ipilimumab alone, versus 43.2 months among participants who received local consolidative therapy alongside the dual immunotherapy, resulting in a hazard ratio of 1.14 (95% CI, 0.75-1.74; P=.54).
Median progression-free survival stood at 24.3 months for the immunotherapy-only group versus 31.3 months for the consolidative therapy group (HR 0.79; 95% CI, 0.54-1.15; P=.22).
Focusing specifically on the subset of patients with oligometastatic disease at randomization yielded a similar divergence. When utilizing immunotherapy alone, median overall survival reached 75.8 months, whereas adding local consolidative therapy resulted in a median overall survival of 42 months. Median progression-free survival in this subgroup was 44.0 months compared to 35.7 months.
Safety and Toxicity Profiles
While severe side effects did not spike overall in the treatment arm, specific toxicities warranted close monitoring. Lung inflammation, known as pneumonitis, happened more frequently in patients receiving local consolidative therapy, and blood counts dropped significantly when systemic treatment was restarted.
The trial data indicate that although combining local radiation or surgery with maintenance immunotherapy remains technically feasible, the approach does not translate into a survival advantage for patients with metastatic non-small cell lung cancer following dual checkpoint blockade.
Keep reading